FDA Warns Internet Pharmacies About Nicotine Lollipops, Lip Balms

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

ROCKVILLE, Maryland-The Food and Drug Administration has warned three Internet pharmacies selling nicotine-laced lollipops and lip balms as smoking cessation aids that the products appear to be illegal and ordered them pulled from the marketplace.

ROCKVILLE, Maryland—The Food and Drug Administration has warned three Internet pharmacies selling nicotine-laced lollipops and lip balms as smoking cessation aids that the products appear to be illegal and ordered them pulled from the marketplace.

The agency said the products are compounded and sold without a physician’s prescription and are intended for use as "drugs." It also expressed concerns that the candy-like products pose a risk of accidental use by children.

The FDA’s concerns arose from statements posted on the pharmacies’ websites. These included claims that the products help alleviate the "hand to mouth fixation" associated with smoking and are a "convenient, tasty way" to replace the cigarette habit, the agency said.

The lollipops and lip balms contain nicotine salicylate (which is not FDA approved for use by pharmacists in compounding drugs), natural sweeteners, and flavorings in a sugar-free base and are available in 0.5 mg to 4 mg dosages.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.